对乙酰氨基苯酚_MSDS_作用_用途_CAS号【103-90-2】

Acetaminophen (paracetamol) 是选择性环氧合酶-2 (COX-2) 的抑制剂,IC50 值为 25.8 μM。它是广泛使用的解热和止痛药。

点击显示

本品为解热镇痛药，通过抑制环氧化酶，选择性抑制下丘脑体温调节中枢前列腺素的合成，导致外周血管扩张、出汗而达到解热的作用，其解热作用强度与阿司匹林相似;通过抑制前列腺素等的合成和释放，提高痛阈而起到镇痛作用，属于外周性镇痛药，作用较阿司匹林弱，仅对轻、中度疼痛有效。本品无明显抗炎作用。

点击显示

[ 描述 ]:

Acetaminophen (paracetamol) 是选择性环氧合酶-2 (COX-2) 的抑制剂,IC50 值为 25.8 μM。它是广泛使用的解热和止痛药。

[ 相关类别 ]:

信号通路 >> 免疫及炎症 >> COX

研究领域 >> 炎症/免疫

天然产物 >> 苯丙酸类

[ 靶点 ]

COX-2:25.8 μM (IC50)

COX-1:113.7 μM (IC50)

Human Endogenous Metabolite

[体外研究]

在体外,对乙酰氨基酚引起对COX-2抑制的4.4倍选择性(COX-1的IC50为113.7μM; COX-2的IC50为25.8μM)。口服给药后,最大离体抑制为56％(COX-1)和83％(COX-2)。在给药后至少5小时,对乙酰氨基酚血浆浓度保持在COX-2的体外IC 50之上。离体IC 50值(COX-1：105.2μM; COX-2：26.3μM)的对乙酰氨基酚与其体外IC 50值相比是有利的。与先前的概念相反,对乙酰氨基酚抑制COX-2超过80％,即与非甾体抗炎药(NSAID)和选择性COX-2抑制剂相当的程度。然而,没有达到> 95％COX-1阻断与抑制血小板功能有关[1]。 MTT测定显示,50mM剂量的对乙酰氨基酚(APAP)显着(p <0.001)使细胞活力降低至61.5±6.65％。有趣的是,与对乙酰氨基酚处理的细胞相比,在对乙酰氨基酚/ HV110共处理细胞中观察到细胞存活率显着(p <0.01)增加至79.7±2.47％[2]。

[体内研究]

对小鼠施用对乙酰氨基酚(250 mg/kg,口服)导致肝脏损伤和细胞坏死显着(p <0.001),血清肝酶丙氨酸氨基转移酶(ALT),氨基转移酶(AST),碱性磷酸酶(ALP)升高证明和γ-谷氨酰转移酶(γGT)与正常组比较。相反,不同剂量柠檬醛(125,250和500 mg/kg)预处理的效果显示ALT血清活性显着(p <0.05)降低(分别为91.79％,93.07％和95.61％), AST(分别为93.40％,91.89％和96.52％),ALP(分别为39.29％,37.07％和59.80％)和γGT(分别为92.83％,91.59％和93.0％),与对乙酰氨基酚组相比。 SLM预处理对ALT活性(95.90％),AST(95.03％),ALP(70.52％)和γGT(92.69％)的影响相似[3]。

[细胞实验]

人肝癌细胞系HepG2在补充有10％胎牛血清（FBS），100U / mL青霉素和100μg/ mL链霉素和2mM L-谷氨酰胺的低葡萄糖DMEM中培养。将细胞保持在37cm的75cm 2烧瓶中，在含有5％CO 2的潮湿气氛中，并且每5天以80％汇合度分开。将细胞接种在24孔板（2×10 5个细胞）中，并在37℃下孵育过夜，然后用含有高葡萄糖浓度的完全DMEM预处理细胞，以下调自噬。 6小时后，用从发酵乳杆菌BGHV110菌株（HV110）获得的不同浓度的后生物处理细胞，以选择合适的剂量用于进一步的实验。将生物素溶解在完全DMEM培养基中并以特定的最终浓度添加到细胞中。在所有其他实验中，接种细胞用50mM对乙酰氨基酚单独处理或用50mM对乙酰氨基酚和选定剂量的冻干HV110共处理。为了分析自噬通量，在处理的同时，将细胞暴露于浓度为25μM的溶酶体药物氯喹，以抑制自噬体 - 溶酶体融合[2]。

[动物实验]

小鼠[3]使用雄性Swiss小鼠（30-40g）。将实验动物分成六组，每组五只动物。首先，每组在7天内口服接受以下治疗：第I组：小鼠未接受任何治疗（正常）。第II组：小鼠接受柠檬醛载体（0.1％吐温80溶液）。组III-V：小鼠分别以125,250和500mg / kg的剂量用柠檬醛预处理。第VI组：用保肝标准药物水飞蓟素（SLM）（200mg / kg）预处理小鼠。此后，动物禁食8小时，然后在第7天以250mg / kg的剂量在组II-VI中接受口服对乙酰氨基酚。组I口服接受含有0.1％吐温80溶液（对乙酰氨基酚载体）的盐水。将储备溶液用作50mg / mL的第一浓度，然后在0.1％吐温80溶液中稀释以制备25和12.5mg / mL的溶液。给予对乙酰氨基酚12小时后，收集血清样品和肝组织，然后进行生物化学和组织学分析。

[参考文献]

[1]. Hinz, B, et al. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J, 2008. 22(2): p. 383-90.

[2]. Dini? M, et al. Lactobacillus fermentum Postbiotic-induced Autophagy as Potential Approach for Treatment ofAcetaminophen Hepatotoxicity. Front Microbiol. 2017 Apr 6;8:594.

[3]. Uchida NS, et al. Hepatoprotective Effect of Citral on Acetaminophen-Induced Liver Toxicity in Mice. Evid Based Complement Alternat Med. 2017;2017:1796209.

[相关活性小分子]

[ 密度 ]:
1.3±0.1 g/cm3

[ 沸点 ]:
387.8±25.0 °C at 760 mmHg

[ 熔点 ]:
168-172 °C(lit.)

[ 分子式 ]:
C₈H₉NO₂

[ 分子量 ]:
151.163

[ 闪点 ]:
188.4±23.2 °C

[ 精确质量 ]:
151.063324

[ PSA ]:
49.33000

[ LogP ]:
0.34

[ 外观性状 ]:
白色粉末或晶体

[ 蒸汽压 ]:
0.0±0.9 mmHg at 25°C

[ 折射率 ]:
1.619

[ 储存条件 ]:
Store at RT

[ 水溶解性 ]:
14 g/L (20 ºC)

详细MSDS(安全技术说明书)

CHEMICAL IDENTIFICATION

RTECS NUMBER :: AE4200000

CHEMICAL NAME :: Acetanilide, 4'-hydroxy-

CAS REGISTRY NUMBER :: 103-90-2

BEILSTEIN REFERENCE NO. :: 2208089

LAST UPDATED :: 199806

DATA ITEMS CITED :: 92

MOLECULAR FORMULA :: C8-H9-N-O2

MOLECULAR WEIGHT :: 151.18

WISWESSER LINE NOTATION :: QR DMV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 591 mg/kg/2D-I

TOXIC EFFECTS :: Liver - liver function tests impaired Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - aplastic anemia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 4962 ug/kg

TOXIC EFFECTS :: Gastrointestinal - changes in structure or function of endocrine pancreas Liver - liver function tests impaired Blood - other changes

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 714 mg/kg

TOXIC EFFECTS :: Liver - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - infant

DOSE/DURATION :: 1440 mg/kg/6D

TOXIC EFFECTS :: Behavioral - irritability Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - body temperature increase

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human

DOSE/DURATION :: 143 mg/kg

TOXIC EFFECTS :: Behavioral - general anesthetic

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 360 mg/kg/2D

TOXIC EFFECTS :: Gastrointestinal - nausea or vomiting Liver - other changes Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 801 mg/kg

TOXIC EFFECTS :: Behavioral - general anesthetic Gastrointestinal - nausea or vomiting Liver - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 714 mg/kg

TOXIC EFFECTS :: Cardiac - EKG changes not diagnostic of specified effects

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human

DOSE/DURATION :: 357 mg/kg

TOXIC EFFECTS :: Behavioral - anorexia (human) Behavioral - coma Gastrointestinal - nausea or vomiting

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 260 mg/kg

TOXIC EFFECTS :: Behavioral - coma Gastrointestinal - nausea or vomiting Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 490 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Gastrointestinal - other changes Kidney, Ureter, Bladder - other changes

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 143 mg/kg/24H-I

TOXIC EFFECTS :: Behavioral - anorexia (human) Liver - hepatitis (hepatocellular necrosis), zonal Liver - jaundice, other or unclassified

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 650 mg/kg

TOXIC EFFECTS :: Vascular - BP lowering not characterized in autonomic section Vascular - other changes Nutritional and Gross Metabolic - metabolic acidosis

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Cardiac - other changes Lungs, Thorax, or Respiration - acute pulmonary edema Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Behavioral - coma Liver - liver function tests impaired Nutritional and Gross Metabolic - metabolic alkalosis

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1944 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1205 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - tremor

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 338 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 367 mg/kg

TOXIC EFFECTS :: Behavioral - analgesia Nutritional and Gross Metabolic - body temperature decrease

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 310 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 2 gm/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Blood - changes in spleen Nutritional and Gross Metabolic - body temperature decrease

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 826 mg/kg

TOXIC EFFECTS :: Behavioral - analgesia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 2620 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Behavioral - tremor

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Amphibian - frog

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - ataxia Lungs, Thorax, or Respiration - other changes

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 512 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 891 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 105 gm/kg/35D-C

TOXIC EFFECTS :: Liver - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 68 gm/kg/13W-C

TOXIC EFFECTS :: Liver - other changes Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 6080 mg/kg/19D-I

TOXIC EFFECTS :: Gastrointestinal - other changes Liver - changes in liver weight Blood - changes in leukocyte (WBC) count

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1600 mg/kg/2D-I

TOXIC EFFECTS :: Liver - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - cytochrome oxidases (including oxidative phosphorylation)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 136 gm/kg/13W-C

TOXIC EFFECTS :: Liver - other changes Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 336 gm/kg/40W-C

TOXIC EFFECTS :: Liver - hepatitis (hepatocellular necrosis), diffuse Liver - other changes Liver - changes in liver weight

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 164 gm/kg/78W-C

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Kidney, Ureter, Bladder - tumors

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 135 gm/kg/77W-C

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Liver - hepatitis (hepatocellular necrosis), zonal Liver - tumors

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 270 gm/kg/77W-C

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Endocrine - other changes

TYPE OF TEST :: TD - Toxic dose (other than lowest)

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 329 gm/kg/78W-C

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 650 mg/kg

SEX/DURATION :: female 29 week(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - Apgar score (human only) Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - other postnatal measures or effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 417 mg/kg

SEX/DURATION :: female 20 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - hepatobiliary system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1300 mg/kg

SEX/DURATION :: female 31-32 week(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Effects on Newborn - other neonatal measures or effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1500 mg/kg

SEX/DURATION :: female 8-19 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 12500 mg/kg

SEX/DURATION :: female 14 day(s) pre-mating female 1-11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1 gm/kg

SEX/DURATION :: female 3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - other postnatal measures or effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 35 gm/kg

SEX/DURATION :: male 70 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - other effects on male

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 25 mg/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 600 mg/kg

SEX/DURATION :: male 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2500 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2500 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2 gm/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: Micronucleus test

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: Sister chromatid exchange

TYPE OF TEST :: Unscheduled DNA synthesis

TYPE OF TEST :: Micronucleus test

TYPE OF TEST :: DNA damage

TYPE OF TEST :: Unscheduled DNA synthesis

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: Sister chromatid exchange

TYPE OF TEST :: Sex chromosome loss and nondisjunction

MUTATION DATA

TYPE OF TEST :: Sister chromatid exchange

TEST SYSTEM :: Rodent - hamster Lung

DOSE/DURATION :: 1 mmol/L

REFERENCE :: MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986- Volume(issue)/page/year: 3,51,1988 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 IARC Cancer Review:Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 TOXICOLOGY REVIEW JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 12,27,1974 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 3(3),100,1973 TOXICOLOGY REVIEW CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 12,601,1978 TOXICOLOGY REVIEW NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB282-666 TOXICOLOGY REVIEW OBGNAS Obstetrics and Gynecology. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1953- Volume(issue)/page/year: 58,57S,1981 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80396 No. of Facilities: 1829 (estimated) No. of Industries: 7 No. of Occupations: 14 No. of Employees: 9269 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80396 No. of Facilities: 1261 (estimated) No. of Industries: 7 No. of Occupations: 26 No. of Employees: 65107 (estimated) No. of Female Employees: 56260 (estimated)

点击显示

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302-H315-H317-H319

[ 警示性声明 ]:
P280-P301 + P312 + P330-P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xn

[ 风险声明 (欧洲) ]:
R22:Harmful if swallowed. R36/37/38:Irritating to eyes, respiratory system and skin . R52/53:Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment . R36/38:Irritating to eyes and skin . R40:Limited evidence of a carci

[ 安全声明 (欧洲) ]:
S26-S36-S61-S37/39

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
1

[ RTECS号 ]:
AE4200000

[ 海关编码 ]:
29242930

对乙酰氨基苯酚上游产品

对乙酰氨基苯酚下游产品

对氨基酚乙酰化而得。方法1：将对氨基酚加入稀乙酸中，再加入冰醋酸，升温至150℃反应7h，加入乙酐，再反应2h，检查终点，合格后冷却至25℃以下，甩滤，水洗至无乙酸味，甩干，得粗品。方法2：将对氨基酚、冰醋酸及含酸50%以上的酸母液一起蒸馏，蒸出稀酸的速度为每小时馏出总量的十分之一，待内温升至130℃以上，取样检查对氨基酚残留量低于2.5%，加入稀酸（含量50%以上），冷却结晶。甩滤，先用少量稀酸洗涤，再用大量水洗至滤液接近无色，得粗品。方法1的收率为90%，方法2的收率为90-95%。精制方法：将水加热至近沸时投入粗品。升温至全溶，加入用水浸泡过的活性炭，用稀乙酸调节至pH=4.2-4.6，沸腾10min。压滤，滤液加少量重亚硫酸钠。冷却至20℃以下，析出结晶。甩滤，水洗，干燥得原料药扑热息痛成品。其他的生产方法还有：（1）在冰醋酸中用锌还原对硝基苯酚，同时乙酰化得到对乙酰氨基酚；（2）将对羟基苯乙酮生成的腙，置于硫酸酸性溶液中，加入亚硝酸钠，转位生成对乙酰氨基酚。

点击显示

[ 海关编码 ]: 29242930

Characterization of a highly sensitive and selective novel trapping reagent, stable isotope labeled glutathione ethyl ester, for the detection of reactive metabolites.

J. Pharmacol. Toxicol. Methods 76 , 83-95, (2015)

Glutathione (GSH) trapping assays are widely used to predict the post-marketing risk for idiosyncratic drug reactions (IDRs) in the pharmaceutical industry. Although several GSH derivatives have been ...

Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury.

Sci. Rep. 5 , 8521, (2015)

Overdosing of the analgesic acetaminophen (APAP, paracetamol) is a major cause of acute liver injury. Whereas toxicity is initiated by hepatocyte necrosis, course of disease is regulated by mechanisms...

Simple and reliable HPLC method for the monitoring of methotrexate in osteosarcoma patients.

J. Chromatogr. Sci. 52(7) , 590-5, (2014)

Methotrexate (MTX) is a dihydrofolate reductase inhibitor that is used for the treatment of tumors and autoimmune diseases. Several automated binding assays are used in clinical practice and numerous ...

更多文献

公司名：上海化源世纪贸易有限公司

区域：上海市普陀区

价格：

联系人：徐经理

产品详情：N-(4-羟基苯基)乙酰胺

公司名：上海吉至生化科技有限公司

区域：上海市奉贤区

价格：
￥88.0/100g ￥268.0/500g ￥128.0/100mg

联系人：刘佳

产品详情：对乙酰氨基苯酚

公司名：上海源溪生物科技有限公司

区域：上海市浦东新区

价格：
￥需询单/1g

联系人：赖经理

产品详情：Acetaminophen

公司名：上海脉铂医药科技有限公司

区域：上海市嘉定区

价格：
￥539.0/1g ￥559.0/10g ￥409.0/5g ￥需询单/1g

联系人：李先生

产品详情：Acetaminophen

公司名：上海阿拉丁生化科技股份有限公司

区域：上海市浦东新区

价格：
￥381.9/1g ￥1606.9/5g ￥67.9/100g ￥33.9/25g

联系人：阿拉丁

产品详情：对乙酰氨基苯酚

查看所有供应商请点击：

对乙酰氨基苯酚供应商

对乙酰氨基酚生物活性是什么

2018-10-03 19:14:57

对乙酰氨基酚是止痛药(止痛药)和退热剂(解热药)。它被发现在非处方药，如泰诺和ExeDrin。它被广泛用于治疗慢性和急性疼痛，并被认为具有类似于其他非处方镇痛剂，如阿司匹林和布洛芬的镇痛效力。其化学名称为4-羟基丙烷化物。早在十九世纪后期，醋氨酚就被用作止痛药。1950年，在发现与扑热息痛密切相关...

对乙酰氨基酚的副作用

2018-10-08 08:24:59

对乙酰氨基酚是一种止痛药和减退剂。对乙酰氨基酚用于治疗许多疾病，如头痛，肌肉疼痛，关节炎，背痛，牙痛，感冒和发烧。对乙酰氨基酚的副作用有哪些呢？常见的副作用包括：发烧。有关不良反应的完整列表，请参见下文。如下服用对乙酰氨基酚的副作用适用于对乙酰氨基酚：胶囊，胶囊液填充，酏剂，液体，粉末，溶液用粉末...

扑热息痛是什么药_扑热息痛的副作用和用量说明书

2018-10-13 17:34:43

扑热息痛是一种止痛药和减退剂，为白色结晶或结晶性粉末；无臭，味微苦。扑热息痛的学名叫扑热息痛，泰诺、白加黑、百服宁、快克等常用的药品中都有这种成分。扑热息痛解热作用较强，镇痛的作用相对较弱。用于治疗许多疾病，如头痛，肌肉疼痛，关节炎，背痛，牙痛，感冒和发烧。一、扑热息痛是什么药？扑热息痛适用于缓解...

对乙酰氨基苯酚

对乙酰氨基苯酚用途

对乙酰氨基苯酚作用

对乙酰氨基苯酚名称

对乙酰氨基苯酚生物活性

对乙酰氨基苯酚物理化学性质